Skip to Content
  • Previous Rank
    57
  • Revenues ($M)
    $53,647.0
  • Revenue Percent Change
    2.1%
  • Profits ($M)
    $11,153.0
  • Profits Percent Change
    -47.7%
  • Assets ($M)
    $159,422.0
  • Employees
    92,400

In Ian Read’s final year as the company’s CEO, Pfizer managed to grow revenues by just 2% as it adjusted to greater competition to—and diminished sales of—Viagra and other drugs on which the company lost patent exclusivity in 2017. The pharmaceutical giant is now in the midst of a reorganization since announcing in the summer of 2018 that it would separate its business into three parts, one of which (its consumer health division) it plans to merge into a joint venture with GlaxoSmithKline. The moves are designed to position Pfizer for greater sales growth under new CEO Albert Bourla.

Company Info

CEO
Albert Bourla
CEO Title
Chief Executive Officer & Director
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
New York, N.Y.
Websitehttp://www.pfizer.com
Years on Fortune 500 List65
Employees92,400
Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Purchase Now

Pfizer Rank History

placeholder

Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$53,647.02.1%
Profits ($M)$11,153.0-47.7%
Assets ($M)$159,422.0-
Total Stockholder Equity ($M)$63,407.0-

Profit Ratios

Profit as % of Revenues20.8%
Profits as % of Assets7.0%
Profits as % of Stockholder Equity17.6%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)1.87
EPS % Change (from 2017)-46.9%
EPS % Change (5 year annual rate)-10.1%
EPS % Change (10 year annual rate)4.5%

Total Return

Total Return to Investors (2018)24.7%
Total Return to Investors (5 year, annualized)11.2%
Total Return to Investors (10 year, annualized)13.8%